Printer Friendly

New Research Estimates Cytokine-Based Drug Sales Account for Roughly 20% of the World Biopharmaceutical Market.

DUBLIN, Ireland -- Research and Markets ( has announced the addition of "Current Drug Development Market for Cytokines, Chemokines and Growth Factors" to their offering.

"Current Drug Development Market for Cytokines, Chemokines and Growth Factors" focuses primarily on the cytokine market, company pipelines and trials in the field of cytokine research. This report succinctly details all the latest advances in the push to market of cytokine-based therapeutics: which products have evolved, which have failed and new players on the field. Primary readers will have comprehensive updates on relevant company pipelines.

Unique to this report is the comprehensive nature of compiled biological response modifiers currently in clinical testing. From the many interleukins to the vast array of growth factors, most all currently developed monoclonals, diabodies, soluble receptors, vaccines, small molecule antagonists, peptide mimetics, recombinantly altered antigens, as well as RNA interference and gene therapy vectors and plasmids are covered.

Also unique is the easy reference tables provided for "at-a-glance" assessment of developmental pipeline progress.

Market projection

* The authors estimate that 2008 biopharma sales statistics covering cytokines will be in the range of:

* Total world market, in terms of corporate revenues from biopharmaceutical sales, is probably about $80 - 100 billion

* The largest portion of sales, of about 50 - 60% involves recombinant proteins, including recombinant monoclonal antibodies. Interferon cytokine's sales alone currently account for $1billion in revenues and is forecast to reach $3.5 billion by the end of the decade. This represents a dramatic 75% increase in 2005 market estimates

* Other major sectors in terms of sales are vaccines ($15 billion), and human plasma-derived proteins (~$10 billion), with all other biopharmaceuticals accounting for $10 or more billion in sales

* There could well be another $5 billion in sales of miscellaneous biosimilars, as older cytokine recombinant patents expire

* Overall, cytokine-based drug sales seem to account for ~20% of the world biopharmaceutical market

Report Benefits

* Identify which companies continue to leverage cytokine-based drugs and which companies license off developed cytokine technologies

* Examine details on which small biotech start-up R&D pipelines are seeking big pharma development on a cytokine to cytokine basis

* Explore products that continue to advance in the FDA approval cycle, seeking expanded label-uses

* Research novel and newly discovered cytokine applications and pathways, which are highlighted to facilitate future drug discovery.

Start-up ventures are given a firm footing in the vast landscape of cytokine drug discovery and development and big pharma will be informed as to which of the many small biotech companies may meet their partnering or acquisition needs.
Companies mentioned:

- Anacor Pharmaceuticals
- Angiogenix
- Antisense Pharma
- BioMimetic
- Biopharm GmbH
- BioVex
- Cantabria
- Domantis
- ESBATech
- Nautilus Biotech
- Neovacs
- Pivotal BioSciences
- Renovo
- Scil Technology
- Uriach
- Vaccinex
- Xencor
- Yes Biotech

For more information visit
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 2, 2007
Previous Article:Provo Craft(R) Awarded Creating Keepsakes' Readers' Choice 'Best New Product of 2006' for the Cricut(TM) Personal Electronic Cutter(TM).
Next Article:Take a Look at the Key Drivers in the US Sports Equipment Market.

Related Articles
Urban outfitted.
Regeneron Announces First Quarter 2001 Results.
Dyax Announces Collaboration with Baxter to Discover Anti-MIF Antibody.
Research and Markets: Cytokines, Chemokines, and Growth Factors- Key Targets for Immunotherapeutic Development.
Research and Markets: Cytokine-Based Research Continues to Revolutionise the Treatment of Inflammatory, Infectious, and Neoplastic Diseases. Pharma Focus: Biotech Manufacturing Tech Profile.
Takeda Pharmaceutical Receives FDA Fast Track Designation for TAK-242, Investigational Compound for Severe Sepsis.
Apollo Life Science's Human Proteins Lead To Improved Cancer Treatment by Boosting Stem Cell Growth.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters